Cell therapy: FDA IND clearance enables CD94-targeted CAR T phase I

The University of Texas MD Anderson received IND clearance from the FDA to start a Phase I trial of JV-394, a CD94-targeted CAR T-cell therapy for relapsed or refractory CD94-positive T/NK-cell lymphomas. The decision allows clinical testing to begin for a population with limited options. CD94-targeting is intended to refine cell targeting by leveraging CD94 expression patterns in the selected lymphoma subgroup. The trial will evaluate initial safety and define dose-escalation parameters. This filing adds another CD94-directed strategy to the expanding CAR T and CAR NK landscape, where cell-surface marker selection is increasingly used to broaden the number of addressable oncology targets.